REGENXBIO Reports Strong Financial Results Amid Advancements in Gene Therapy for Rare Diseases

On August 6, 2026, REGENXBIO Inc. (Nasdaq: RGNX) released its financial results for the second quarter of the year, showcasing a robust pipeline and significant advancements in its gene therapy initiatives. The company revealed substantial milestones, particularly regarding treatments for Duchenne muscular dystrophy (Duchenne), diabetic retinopathy (DR), and wet age-related macular degeneration (wet AMD).

Key Financial Highlights

In Q2 2026, REGENXBIO reported revenues of $108 million, a significant increase from $21.4 million in the same period last year. This remarkable jump was driven mainly by a $100 million milestone payment from AbbVie upon the dosing of the first patient in a key study focused on diabetic retinopathy. The company’s cash position also improved post-quarter, with over $200 million raised in July alone, ensuring operational funding well into 2027.

The firm's total cash, cash equivalents, and marketable securities exceeded $310 million, positioning it strongly for upcoming trials and regulatory submissions. The positive financial trajectory underscores the company's commitment to delivering innovative gene therapies to the market.

Advancements in Clinical Trials

REGENXBIO is making headway in its clinical trials across various therapeutic areas. The RGX-202 for Duchenne has garnered attention, with its BLA submission on track to begin in Q3 of this year, potentially leading to accelerated approval by late 2027.
- Clinical Outcomes: The Phase III AFFINITY DUCHENNE trial successfully met its primary endpoint with high statistical significance (p<0.0001), verging on realizing the full potential of RGX-202 as a leading therapy for Duchenne.
- Patient Impact: The confirmatory study concluded enrollment ahead of schedule, indicating strong interest and demand from the patient community.

In addition, the anticipated release of topline data from pivotal studies for surabgene lomparvovec (ABBV-RGX-314) in the treatment of wet AMD is expected in Q4 2026, and a trial for diabetic retinopathy continues to progress smoothly.

Future Expectations

Executives at REGENXBIO highlighted that the company is well-prepared for upcoming regulatory interactions. The FDA validated the strategy for RGX-121, a potential first-in-class treatment for Hunter syndrome, reaffirming that no further studies are needed prior to its BLA resubmission, also scheduled for Q3 2026.

Curran Simpson, President and CEO of REGENXBIO, expressed optimism regarding the company’s trajectory: "With strong clinical execution and an extended cash runway, we are well-positioned to advance multiple high-value programs and transform the lives of patients suffering from rare genetic disorders."

Conclusion

REGENXBIO's second quarter results reflect not only a strong financial status but also a commitment to advancing critical gene therapies. The potential of these innovative treatments, underpinned by solid clinical data, positions REGENXBIO at the forefront of biotechnology innovation. As it moves towards regulatory submissions and achieves critical milestones, the company continues its journey to improve patient outcomes and redefine treatment paradigms for complex diseases.